Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Complement Receptors in Shock and Transplantation

Complement Receptors in Shock and Transplantation Abstract Over the last decade, elegant studies of the basic biologic characteristics of inflammation and tissue injury have implicated leukocyte-mediated vascular and tissue injury in the pathogenesis of a wide variety of immune and inflammatory clinical disorders, including allograft rejection, adult respiratory distress syndrome, and shock. Recognition of the importance of leukocyte adherence to the endothelium in the pathogenesis of these disorders, in combination with advances in cellular and molecular biology, have led to the development of novel therapeutic approaches to the treatment of immune and inflammatory disorders in which leukocytes contribute to vascular and tissue injury. Several of these promising new therapeutic approaches have focused on the complement system. Examples of this therapeutic approach include the use of monoclonal antibodies directed at leukocyte complement receptors and the administration of soluble complement receptors to inhibit the binding of leukocytes to the endothelium. Because of the biologic and significant potential clinical importance of these advances, in this review, we focus on the complement system and complement receptor-mediated tissue injury. (Arch Surg. 1993;128:1222-1226) References 1. Deitch EA. Multiple organ failure: pathophysiology and potential future therapy . Ann Surg . 1992;216:117-134.Crossref 2. Polombo JD, Blackburn GL, Forse RA. Endothelial cell factors and response to injury . Surg Gynecol Obstet . 1991;173:505-518. 3. Ross GD. Complement and complement receptors . CurrOpin Immunol . 1989; 2:50-62.Crossref 4. Krych M, Atkinson JP, Holers VM. Complement receptors . Curr Opin Immunol . 1992;4:8-13.Crossref 5. Becherer JD, Alsenz J, Servis C, Myones BL, Lambris JD. Cell surface proteins reacting with activated complement components . Complement Inflamm . 1989; 6:142-165. 6. Ross GD. Complement receptor 1 . Curr Top Microbiol Immunol . 1992;178:31-44. 7. Harlan JM, Liu DY. Adhesion: its role in inflammatory disease . In: Breakthroughs in Molecular Biology Series . New York, NY: WH Freeman & Co; 1992: 19-42. 8. Pober JS, Cotran RS. Cytokines and endothelial cell biology . Physiol Rev . 1990; 70:427-451. 9. Redl H, Dinges HP, Buurman WA, et al. Expression of endothelial leukocyte adhesion molecule-1 in septic but not traumatic/hypovolemic shock in the baboon . Am J Pathol . 1991;139:461-466. 10. Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits . J Clin Invest . 1988;81:939-944.Crossref 11. Mileski WJ, Winn RK, Vedder NB, Pohlman MD, Harlan JM, Rice CL. Inhibition of CD18-dependent neutrophil adherence reduces organ injury after hemorrhagic shock in primates . Surgery . 1990;108:206-212. 12. Oliver MG, Specian RD, Perry MA, Granger DN. Morphologic assessment of leukocyte-endothelial cell interactions in mesenteric venules subjected to ischemia reperfusion . Inflammation . 1991;15:331-346.Crossref 13. Jaeschke H, Farhood A, Smith CW. Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent mechanism . Am J Physiol . 1991; 261:G1051-G1056. 14. Mulligan MS, Johnson KJ, Todd RF, et al. Requirements for leukocyte adhesion molecules in nephrotoxic nephritis . J Clin Invest . 1993;91:577-587.Crossref 15. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis . Science . 1990;249:146-151.Crossref 16. Lindsay TF, Hill J, Oritz F, et al. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion . Ann Surg . 1992;216:677-683.Crossref 17. Dana N, Fathallah DM, Arnout MA. Expression of a soluble and functional form of human β2 integrin CD11b/CD18 . Proc Natl Acad Sci U S A . 1991;88:3106-3110.Crossref 18. Knechtle SJ, Halperin EC, Murphy CE, et al. The effect of cyclosporin, total lymphoid irradiation, and cobra venom factor on hyperacute rejection . J Heart Transplant . 1985;4:541-545. 19. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement . Transplantation . 1993;55:857-866.Crossref 20. Platt JL, Lindman BJ, Geller RL, et al. The role of natural antibodies in the activation of xenogenic endothelial cells . Transplantation . 1991;52:1037-1043.Crossref 21. Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection . J Surg Res . 1991;50:350-355.Crossref 22. Pruitt SK, Baldwin WM, Marsh HC, Linss Yeh CG, Bollinger RR. Effect of soluble complement receptor type 1 on natural antibody levels during xenograft rejection . Transplant Proc . 1992;24:477-478. 23. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor . Transplantation . 1991;52:530-533.Crossref 24. Fearon DT. Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors . Clin Exp Immunol . 1991;86( (suppl) ):43-46.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Complement Receptors in Shock and Transplantation

Archives of Surgery , Volume 128 (11) – Nov 1, 1993

Loading next page...
 
/lp/american-medical-association/complement-receptors-in-shock-and-transplantation-AQI5tYBXD8

References (29)

Publisher
American Medical Association
Copyright
Copyright © 1993 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1993.01420230050008
Publisher site
See Article on Publisher Site

Abstract

Abstract Over the last decade, elegant studies of the basic biologic characteristics of inflammation and tissue injury have implicated leukocyte-mediated vascular and tissue injury in the pathogenesis of a wide variety of immune and inflammatory clinical disorders, including allograft rejection, adult respiratory distress syndrome, and shock. Recognition of the importance of leukocyte adherence to the endothelium in the pathogenesis of these disorders, in combination with advances in cellular and molecular biology, have led to the development of novel therapeutic approaches to the treatment of immune and inflammatory disorders in which leukocytes contribute to vascular and tissue injury. Several of these promising new therapeutic approaches have focused on the complement system. Examples of this therapeutic approach include the use of monoclonal antibodies directed at leukocyte complement receptors and the administration of soluble complement receptors to inhibit the binding of leukocytes to the endothelium. Because of the biologic and significant potential clinical importance of these advances, in this review, we focus on the complement system and complement receptor-mediated tissue injury. (Arch Surg. 1993;128:1222-1226) References 1. Deitch EA. Multiple organ failure: pathophysiology and potential future therapy . Ann Surg . 1992;216:117-134.Crossref 2. Polombo JD, Blackburn GL, Forse RA. Endothelial cell factors and response to injury . Surg Gynecol Obstet . 1991;173:505-518. 3. Ross GD. Complement and complement receptors . CurrOpin Immunol . 1989; 2:50-62.Crossref 4. Krych M, Atkinson JP, Holers VM. Complement receptors . Curr Opin Immunol . 1992;4:8-13.Crossref 5. Becherer JD, Alsenz J, Servis C, Myones BL, Lambris JD. Cell surface proteins reacting with activated complement components . Complement Inflamm . 1989; 6:142-165. 6. Ross GD. Complement receptor 1 . Curr Top Microbiol Immunol . 1992;178:31-44. 7. Harlan JM, Liu DY. Adhesion: its role in inflammatory disease . In: Breakthroughs in Molecular Biology Series . New York, NY: WH Freeman & Co; 1992: 19-42. 8. Pober JS, Cotran RS. Cytokines and endothelial cell biology . Physiol Rev . 1990; 70:427-451. 9. Redl H, Dinges HP, Buurman WA, et al. Expression of endothelial leukocyte adhesion molecule-1 in septic but not traumatic/hypovolemic shock in the baboon . Am J Pathol . 1991;139:461-466. 10. Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits . J Clin Invest . 1988;81:939-944.Crossref 11. Mileski WJ, Winn RK, Vedder NB, Pohlman MD, Harlan JM, Rice CL. Inhibition of CD18-dependent neutrophil adherence reduces organ injury after hemorrhagic shock in primates . Surgery . 1990;108:206-212. 12. Oliver MG, Specian RD, Perry MA, Granger DN. Morphologic assessment of leukocyte-endothelial cell interactions in mesenteric venules subjected to ischemia reperfusion . Inflammation . 1991;15:331-346.Crossref 13. Jaeschke H, Farhood A, Smith CW. Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent mechanism . Am J Physiol . 1991; 261:G1051-G1056. 14. Mulligan MS, Johnson KJ, Todd RF, et al. Requirements for leukocyte adhesion molecules in nephrotoxic nephritis . J Clin Invest . 1993;91:577-587.Crossref 15. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis . Science . 1990;249:146-151.Crossref 16. Lindsay TF, Hill J, Oritz F, et al. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion . Ann Surg . 1992;216:677-683.Crossref 17. Dana N, Fathallah DM, Arnout MA. Expression of a soluble and functional form of human β2 integrin CD11b/CD18 . Proc Natl Acad Sci U S A . 1991;88:3106-3110.Crossref 18. Knechtle SJ, Halperin EC, Murphy CE, et al. The effect of cyclosporin, total lymphoid irradiation, and cobra venom factor on hyperacute rejection . J Heart Transplant . 1985;4:541-545. 19. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement . Transplantation . 1993;55:857-866.Crossref 20. Platt JL, Lindman BJ, Geller RL, et al. The role of natural antibodies in the activation of xenogenic endothelial cells . Transplantation . 1991;52:1037-1043.Crossref 21. Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection . J Surg Res . 1991;50:350-355.Crossref 22. Pruitt SK, Baldwin WM, Marsh HC, Linss Yeh CG, Bollinger RR. Effect of soluble complement receptor type 1 on natural antibody levels during xenograft rejection . Transplant Proc . 1992;24:477-478. 23. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor . Transplantation . 1991;52:530-533.Crossref 24. Fearon DT. Anti-inflammatory and immunosuppressive effects of recombinant soluble complement receptors . Clin Exp Immunol . 1991;86( (suppl) ):43-46.Crossref

Journal

Archives of SurgeryAmerican Medical Association

Published: Nov 1, 1993

There are no references for this article.